Orlistat [96829-58-2]
O6845
Estimated Purity≥98%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NameOrlistat [96829-58-2]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥98%
- FormatSoluble in DMSO or ethanol.
- Scientific DescriptionFatty acid synthase inhibitor.; Orlipastat, Xenical
- Storage InstructionProtect from light and moisture.; 4°C
- UNSPSC12352200
References
- Kant S, Kumar A, Singh SM. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta. 2014 Jan;1840(1):294-302. PMID: 24060750. Chuang HY, Chang YF, Hwang JJ. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother. 2011 Jul;65(4):286-92. PMID: 21723078. Halpern A, Pepe RB, Monegaglia AP, et al. Efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patients. J Obes. 2010;2010. pii: 602537. PMID: 20871858.